Galderma Group AG (SWX:GALD)

Market Cap	32.12B
Revenue (ttm)	3.73B
Net Income (ttm)	300.62M
Shares Out	237.41M
EPS (ttm)	1.26
PE Ratio	107.03
Forward PE	48.27
Dividend	0.15 (0.11%)
Ex-Dividend Date	Apr 25, 2025

Volume	260,601
Average Volume	1,309,480
Open	135.50
Previous Close	136.50
Day's Range	134.80 - 136.80
52-Week Range	72.70 - 138.80
Beta	n/a
RSI	62.21
Earnings Date	Oct 24, 2025

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,545
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

Financial numbers in USD